Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.

OBJECTIVE Agents that augment GLP-1 effects enhance glucose-dependent beta-cell insulin production and secretion and thus are hoped to prevent progressive impairment in insulin secretion characteristic of type 2 diabetes (T2D). The purpose of this study was to evaluate GLP-1 effects on beta-cell secretory capacity, an in vivo measure of functional b-cell mass, early in the course of T2D. RESEARCH DESIGN AND METHODS We conducted a randomized controlled trial in 40 subjects with early T2D who received the GLP-1 analog exenatide (n = 14), the dipeptidyl peptidase IV inhibitor sitagliptin (n = 12), or the sulfonylurea glimepiride (n = 14) as an active comparator insulin secretagogue for 6 months. Acute insulin responses to arginine (AIR(arg)) were measured at baseline and after 6 months of treatment with 5 days of drug washout under fasting, 230 mg/dL (glucose potentiation of arginine-induced insulin release [AIR(pot)]), and 340 mg/dL (maximum arginine-induced insulin release [AIR(max)]) hyperglycemic clamp conditions, in which AIR(max) provides the beta-cell secretory capacity. RESULTS The change in AIR(pot) was significantly greater with glimepiride versus exenatide treatment (P < 0.05), and a similar trend was notable for the change in AIR(max) (P = 0.1). Within each group, the primary outcome measure, AIR(max), was un-changed after 6 months of treatment with exenatide or sitagliptin compared with baseline but was increased with glimepiride (P < 0.05). alpha-Cell glucagon secretion (AGR(min)) was also increased with glimepiride treatment (P < 0.05), and the change in AGR(min) trended higher with glimepiride than with exenatide (P = 0.06). CONCLUSIONS After 6 months of treatment, exenatide or sitagliptin had no significant effect on functional beta-cell mass as measured by beta-cell secretory capacity, whereas glime-piride appeared to enhance beta- and alpha-cell secretion.